NbN3
Free
3.9.5for iPhone, iPod touch
7.9
6 Ratings
European College of Neuropsychopharmacology (ECNP)
Developer
23.4 MB
Size
Feb 4, 2024
Update Date
Medical
Category
12+
Age Rating
Age Rating
NbN3 Screenshots
About NbN3
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
Show More
What's New in the Latest Version 3.9.5
Last updated on Feb 4, 2024
Old Versions
- Bug fixes.
Show More
Version History
3.9.5
Feb 4, 2024
- Bug fixes.
3.9.4
Dec 31, 2023
- Bug fixes.
3.9.3
Sep 27, 2023
- Bug fixes.
3.9.2
Sep 13, 2023
- Bug fixes.
3.9.1
Jul 6, 2023
- Bug fixes.
3.9
May 23, 2023
- Bug fixes.
3.8
May 9, 2023
- Bug fixes.
3.7
May 5, 2023
- Bug fixes.
3.6
Feb 25, 2023
- Bug fixes.
3.5
Feb 24, 2023
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
3.4
Jan 11, 2022
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
3.3
Nov 24, 2021
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake
3.1
Aug 12, 2021
Performance improvements
3.0
Aug 11, 2021
Performance improvements
2.9
Nov 26, 2020
In this version of the app, we fixed some technical issues and added important information and tools such as: a tutorial video of the app., the mission and scope of the NbN, and lists of the 10 pharmacological domains and 9 modes of action used to classify psychotropics.
2.7
Aug 4, 2019
In this new version, we have included new information on doses for each drug. Another change is related to nomenclature; it was simplified, (e.g., instead of talking about “serotonin reuptake inhibitor” we now use “serotonin inhibitor”), yet the extended terminology is brought as the first line in the neurobiology layer. Furthermore we improved and updated the search engine logic for a better and more intuitive user experience.
2.6
Aug 29, 2018
General improvements
2.5
Aug 26, 2018
General improvements
2.4
May 8, 2018
General improvements.
2.3
Jan 9, 2018
General improvements
2.2
Nov 5, 2017
IOS 11 bug fixes.
2.1
Aug 29, 2017
General improvements
2.0
May 8, 2017
In this updated version we improve and optimize NbN search engine logic by dimensions in order to shorten user search time. Furthermore additional drug were added according to ECNP committee recommendation.
The new and updated version of NbN-2 is an English version, translation to choosen languages will follow.
The new and updated version of NbN-2 is an English version, translation to choosen languages will follow.
1.7.1
May 17, 2016
Additional bug fixes
1.7
May 15, 2016
Bug fixes
NbN3 FAQ
Click here to learn how to download NbN3 in restricted country or region.
Check the following list to see the minimum requirements of NbN3.
iPhone
Requires iOS 12.0 or later.
iPod touch
Requires iOS 12.0 or later.
NbN3 supports English
